Outcome of Hospitalized Cancer Patients with Hypernatremia: A Retrospective Case-Control Study

Hypernatremia (>145 mmol/L) is a relatively rare event, and the data regarding its role in the outcome of inpatients on an oncology ward are weak. The aim of this study was to describe the prevalence, prognosis, and outcome of hospitalized cancer patients with hypernatremia. We performed a retros...

Full description

Saved in:
Bibliographic Details
Published in:Current oncology (Toronto) 2022-11, Vol.29 (11), p.8814-8824
Main Authors: Del Rio, Jessica, Buess, Martin
Format: Article
Language:English
Subjects:
Cancer
Cancer patients
Care and treatment
Case-Control Studies
Hospital patients
Hospitalization
Humans
hypernatremia
Hypernatremia - epidemiology
Hypernatremia - etiology
Hypernatremia - therapy
Neoplasms - complications
Non-Hodgkin's lymphomas
Oncology, Experimental
Patient outcomes
Prognosis
Retrospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hypernatremia (>145 mmol/L) is a relatively rare event, and the data regarding its role in the outcome of inpatients on an oncology ward are weak. The aim of this study was to describe the prevalence, prognosis, and outcome of hospitalized cancer patients with hypernatremia. We performed a retrospective case-control study of data obtained from inpatients with a solid tumor at the St. Claraspital, Basel, Switzerland, who were admitted between 2017 and 2020. The primary endpoint was overall survival. Hypernatremia was found in 93 (3.16%) of 2945 inpatients bearing cancer or lymphoma. From 991 eligible normonatremic control patients, 93 were matched according to diagnosis, age, and sex. The median overall survival time (OS) of patients with hypernatremia was 1.5 months compared to 11.7 months of the normonatremic controls (HR 2.69, 95% CI 1.85-3.90, < 0.0001). OS of patients with irreversible compared to reversible hypernatremia was significantly shorter (23 versus 88 days, HR 4.0, 95% CI 2.04-7.70, < 0.0001). The length of hospital stay was significantly longer for the hypernatremic than for the normonatremic group ( < 0.0001). Significantly more patients with hypernatremia died in the hospital (30.1% versus 8.6%, < 0.001). These results suggest hypernatremia to be associated with an unfavorable outcome and a very short OS.
ISSN:1718-7729
1198-0052
1718-7729
DOI:10.3390/curroncol29110693